Tom Barrows, PhD
President and CSO
Dr. Barrows is responsible for research and is the inventor of CCI’s biomaterials technology. His career in biomedical materials research began after obtaining a PhD in organic chemistry from The Pennsylvania State University and includes 22 years at 3M where he invented and developed bioabsorbable polymers and surgical devices including tissue sealants. He was recruited to join a start-up venture in the Boston area in 1996 to continue research on tissue sealants. From there he relocated to Atlanta, GA and co-founded BioAmide, Inc. and began applying tissue engineering principles to the development of solutions for hair restoration, which led to the acquisition of BioAmide in 2002 by Bosley/Aderans (Aderans, Ltd., Tokyo, Japan) and simultaneous formation of the Aderans Research Institute, Inc. (ARI). In 2008 he left ARI and co-founded CCI with the goal of utilizing stem cells to cure chronic wounds.
Chris Ingraham, PhD
Director of Operations
Dr. Ingraham joined CCI in 2013 and is currently responsible for operations, cell culture research, and product development. After obtaining a B.S. degree from the Rochester Institute of Technology he began working as a cell biologist at the University of Rochester on mitochondrial diseases where he received his Ph.D. in 2007. Subsequently his research focused on the technology of stem cell culture conditions and he continued this work at The Scripps Research Institute in La Jolla, CA. In 2011, Dr. Ingraham entered the field of cell-based hair restoration product development as a Senior Scientist at the Aderans Research Institute in Marietta, GA. His professional goal is aligned with the vision of CCI: to become a pioneer in the field of human cell regenerative therapy.
Edgar B Rey
As Chief Executive Officer, Edgar brings to Cell Constructs over 25 years of experience in the Cardiovascular medical device industry with over 15 Years of executive level management including sales and marketing leadership for a number of startups. He has participated in numerous successful medical device exits and transactions. He is also Managing Director of Life Sciences for Covalent Interests, the lead venture investor in Cell Constructs. Prior to joining Covalent Edgar held key positions at Atricure, nContact, ESTECH, Guidant CVS, CTS, ACS, and Eli Lilly.